Population Pharmacokinetics of Serplulimab and Quantitative Assessment of Transitioning From Weight‐Based to Flat‐Dosing Strategy

Documenti analoghi

• Model‐Informed Dosing Regimen of Sugemalimab for European Patients With Non‐Small Cell Lung Cancer: Bridging From Asian Clinical Data
  di: Yucheng Sheng, et al.
  Pubblicazione: (2026)
• A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population
  di: Yogesh Patel, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics and Exposure‐Response Relationship of Hemoporfin in Pediatric Patients With Port‐Wine Stain
  di: Rong Chen, et al.
  Pubblicazione: (2025)
• Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD
  di: Sahira Chaiben, et al.
  Pubblicazione: (2025)
• Model‐Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models
  di: Yoonjin Kim, et al.
  Pubblicazione: (2025)